Enovis Corporation
Financials
Valuation Metrics
Enovis Corporation's Market Cap is $1.81B. At end of 2025 it was $1.51B. Ranked #2127 of 3,112 in US market (top 68%), #1302 of 1,667 on NYSE (top 78%), #125 of 206 in Health Care Equipment & Services (top 61%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.81B | US#2,127/3,112 Sec#125/206 |
| Revenue | $2.28B | US#1,400/3,112 Sec#86/206 |
| Net Income | $-1.14B | US—/3,112 Sec—/206 |
| Total Assets | $3.83B | US#1,622/3,112 Sec#76/206 |
| Net Assets | $1.48B | US#1,494/3,112 Sec#79/206 |
| Employees | 7,802 | US#682/3,112 Sec#63/206 |
| Value | ||
| P/B | 1.22x | US#560/3,112 Sec#32/206 |
| P/S | 0.79x | US#509/3,112 Sec#38/206 |
| FCF Yield | 1.99% | US#1,960/3,112 Sec#124/206 |
| Profitability | ||
| ROE | -77.00% | US#2,821/3,112 Sec#181/206 |
| ROA | -29.68% | US#2,869/3,112 Sec#190/206 |
| Op. Margin | 2.70% | US#2,259/3,112 Sec#115/206 |
| Revenue Growth | 5.42% | US#1,704/3,112 Sec#129/206 |
| Financial Health | ||
| Debt Ratio | 159.30% | US#1,551/3,112 Sec#140/206 |
| Total Debt | $1.41B | US#1,306/3,112 Sec#66/206 |
| FCF | $36M | US#2,041/3,112 Sec#126/206 |
| Cash | $33M | US#2,739/3,112 Sec#185/206 |
| Current Ratio | 2.04x | US#1,236/3,112 Sec#113/206 |
| Performance | ||
| 1Y Return | 22.07% | US#1,524/3,112 Sec#105/206 |
| 1M Return | 39.64% | US#21/3,112 Sec#5/206 |
| From 52W High | -8.34% | US#897/3,112 Sec#61/206 |
| 1Y MDD | -44.24% | US#2,173/3,112 Sec#125/206 |
| Trading | ||
| Volume | 1,379,937 shares | US#1,192/3,112 Sec#73/206 |
| Trading Value | $43M | US#1,471/3,112 Sec#108/206 |
| Per Share | ||
| EPS | $-20.86 | US—/3,112 Sec—/206 |
| BPS | $26.23 | US#976/3,112 Sec#60/206 |
Company Info
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.